Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Janux Therapeutics Inc (NQ: JANX )

36.90 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 36.90
Bid (Size) 14.76 (2)
Ask (Size) 39.95 (1)
Prev. Close 36.90
Today's Range 36.90 - 36.90
52wk Range 5.650 - 65.60
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Janux Therapeutics Announces Updates to Board of Directors
From Janux Therapeutics
Via Business Wire
GeneDx Leads Russell 2000 This Year As It Shifts To More Comprehensive Genetic Testing
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and record high margins. 
Via Benzinga

Performance

YTD
+234.85%
+234.85%
1 Month
-6.46%
-6.46%
3 Month
-40.00%
-40.00%
6 Month
+315.54%
+315.54%
1 Year
+205.97%
+205.97%

More News

Read More
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
The Latest Analyst Ratings For Janux Therapeutics
Via Benzinga
Analyst Ratings For Janux Therapeutics
Via Benzinga
A Glimpse Into The Expert Outlook On Janux Therapeutics Through 6 Analysts
Via Benzinga
3 Biotech Stocks That Can Gain Exponentially By Leveraging AI
Via Talk Markets
Ambarella Posts Upbeat Results, Joins Gap, PagerDuty, Elastic And Other Big Stocks Moving Higher On Friday
Via Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
Why Janux Therapeutics Stock Is Crushing It This Week
Via The Motley Fool
Forecasting The Future: 4 Analyst Projections For Janux Therapeutics
Via Benzinga
Take the Money and Run: 3 Overbought Stocks to Sell ASAP
Via InvestorPlace
These 3 Biotech Stocks Are Up 269% in 2024. Is There More to Come?
Via InvestorPlace
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
Why Is Cancer-Focused Janux Therapeutics Stock Trading Higher On Thursday?
Via Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
Via Investor's Business Daily
Why Janux Therapeutics Stock Soared as the Market Sagged Today
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Cancer-Focused Janux Therapeutics Platform Has 'Tremendous Opportunity': Analyst
Via Benzinga
JANX Stock Earnings: Janux Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
2 Stocks That Have More Than Tripled This Year: Are They Buys?
Via The Motley Fool
B of A Securities Maintains Buy Rating for Janux Therapeutics: Here's What You Need To Know
Via Benzinga
Why Asana Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.